MAM
Govt pushes for adequate representation in BARC
MUMBAI: Don‘t mistake the alternative television ratings system to be under the total control of the private broadcasters, advertising agencies and the advertisers. The government is pushing for adequate representation inside BARC (Broadcast Audience Research Council), the new entity that will lay out the television audience measurement system in India.
BARC has been formed with the Indian Broadcasting Foundation (IBF) having a 60 per cent stake and the remaining 40 per cent being shared equally between the Advertising Agencies Association of India (AAAI) and the Indian Society of Advertisers (ISA).
Prasar Bharati, the public broadcaster, was to benefit from the formation of BARC as the TV ratings coverage would have spread across wider geographies. Now the government also wants DAVP (Directorate of Advertising and Publicity) , which channelises all advertising spends made by the government, to have some voice.
In a meeting on 4 September called by the government and attended by the IBF, the AAAI and the ISA members, the government has said that it wanted adequate representation. “The Information and Broadcasting ministry asked us what steps were being taken to include the Prasar Bharati and the DAVP (in BARC).They want adequate representation from Prasar Bharati and DAVP to have adequate representation in BARC to look after the Government‘s interest. We have heard the suggestions and will consider them,” AAAI president and Leo Burnett chairman and CEO of India subcontinent Arvind Sharma told Indiantelevision.com.
The meeting was chaired by I&B ministry secretary Uday Kumar Verma.
The three bodies were also asked to nominate an advisory committee on BARC by the end of next week .
“The push has been to move BARC forward. The secretary has asked us (AAAI, IBF and ISA) to nominate a high powered committee whose role will be to guide and advise (on BARC) by the end of next week. We as BARC need to identify and concur on the names,” said Sharma.
During the meeting, the secretary also referred to the Amit Mitra Committee report which suggested that statisticians, sociologists and demographers should form part of the technical committee.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
